1437779-17-3 Usage
Uses
Used in Pharmaceutical Applications:
1-(azetidin-1-yl)-2-(2,6-difluoro-4-hydroxyphenyl)ethanone is used as a compound for drug development due to its unique structural features, including the azetidine ring and the difluoro-hydroxyphenyl group. These characteristics are commonly found in biologically active molecules, suggesting that the compound may possess properties beneficial for creating new medications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(azetidin-1-yl)-2-(2,6-difluoro-4-hydroxyphenyl)ethanone is used as a subject of study to explore its potential interactions with biological targets and its applicability in the design of novel therapeutic agents.
Used in Pharmacology:
1-(azetidin-1-yl)-2-(2,6-difluoro-4-hydroxyphenyl)ethanone is also utilized in pharmacology for further investigation into its pharmacological properties, including its potential effects on biological systems and its suitability for therapeutic use.
Check Digit Verification of cas no
The CAS Registry Mumber 1437779-17-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,3,7,7,7 and 9 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1437779-17:
(9*1)+(8*4)+(7*3)+(6*7)+(5*7)+(4*7)+(3*9)+(2*1)+(1*7)=203
203 % 10 = 3
So 1437779-17-3 is a valid CAS Registry Number.
1437779-17-3Relevant academic research and scientific papers
SUBSTITUTED CYCLOPROPYL COMPOUNDS
-
, (2014/04/17)
Substituted cyclopropyl piperidinyl compounds and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-1 19. Pharmaceutical compositions and methods of treatment are also included.
SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS
-
Page/Page column 113, (2013/06/05)
Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included
